The oncogenic role of hepatitis delta virus in hepatocellular carcinoma

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Puigvehí, Marc
  • dc.contributor.author Moctezuma-Velázquez, Carlos
  • dc.contributor.author Villanueva, Augusto
  • dc.contributor.author Llovet, Josep Maria
  • dc.date.accessioned 2021-04-22T06:49:03Z
  • dc.date.available 2021-04-22T06:49:03Z
  • dc.date.issued 2019
  • dc.description.abstract Hepatitis delta virus (HDV) is a small defective virus that needs hepatitis B virus (HBV) to replicate and propagate. HDV infection affects 20-40 million people worldwide and pegylated interferon (PegIFN) is the only recommended therapy. There is limited data on the contribution of HDV infection to HBV-related liver disease or liver cancer. Evidence from retrospective and cohort studies suggests that HBV/HDV coinfection accelerates progression to cirrhosis and is associated with an increased risk of hepatocellular carcinoma (HCC) development compared to HBV monoinfection. Although the life cycle of HDV is relatively well known, there is only ancillary information on the molecular mechanisms that can drive specific HDV-related oncogenesis. No thorough reports on the specific landscape of mutations or molecular classes of HDV-related HCC have been published. This information could be critical to better understand the uniqueness, if any, of HDV-related HCC and help identify novel targetable mutations. Herein, we review the evidence supporting an oncogenic role of HDV, the main reported mechanisms of HDV involvement and their impact on HCC development.
  • dc.description.sponsorship M. Puigvehi received a scholarship grant from Asociación Española para el Estudio del Hígado (AEEH). A. Villanueva was supported by the DoD Translational Team Science Award (CA150272P3). J.M. Llovet was supported by NCI (P30-CA196521), DoD Translational Team Science Award (CA150272P1), European Commission (EC)/Horizon 2020 Program (HEPCAR, Ref. 667273-2), EIT Health (CRISH2, Ref. 18053), Accelerator Award (CRUCK, AEEC, AIRC) (HUNTER, Ref. C9380/A26813), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (SAF2016-76390), and the Generalitat de Catalunya/AGAUR (SGR-1358).
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Puigvehí M, Moctezuma-Velázquez C, Villanueva A, Llovet JM. The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. JHEP Rep. 2019 May 16; 1(2):120-30. DOI: 10.1016/j.jhepr.2019.05.001
  • dc.identifier.doi http://dx.doi.org/10.1016/j.jhepr.2019.05.001
  • dc.identifier.issn 2589-5559
  • dc.identifier.uri http://hdl.handle.net/10230/47183
  • dc.language.iso eng
  • dc.publisher Elsevier
  • dc.relation.projectID info:eu-repo/grantAgreement/EC/H/667273
  • dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2016-76390
  • dc.rights Copyright © 2019 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
  • dc.subject.keyword HCC
  • dc.subject.keyword Co-infection
  • dc.subject.keyword Hepatitis B virus
  • dc.subject.keyword Defective
  • dc.subject.keyword Liver cancer
  • dc.subject.keyword Molecular pathogenesis
  • dc.subject.keyword Molecular pathogenesis
  • dc.title The oncogenic role of hepatitis delta virus in hepatocellular carcinoma
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)
Documents OpenAIRE (Open Access Infrastructure for Research in Europe)